Biomedical data is growing exponentially, and managing it is increasingly challenging. While Findable, Accessible, Interoperable and Reusable (FAIR) data principles provide guidance, their adoption has proven difficult, especially in larger enterprises like pharmaceutical companies. In this manuscript, we describe how we leverage an Ontology-Based Data Management (OBDM) strategy for digital transformation in Novo Nordisk Research & Early Development. Here, we include both our technical blueprint and our approach for organizational change management. We further discuss how such an OBDM ecosystem plays a pivotal role in the organizations digital aspirations for data federation and discovery fuelled by artificial intelligence. Our aim for this paper is to share the lessons learned in order to foster dialogue with parties navigating similar waters while collectively advancing the efforts in the fields of data management, semantics and data driven drug discovery.

翻译：生物医学数据呈指数级增长，其管理难度日益加大。尽管可发现、可访问、可互操作与可复用（FAIR）数据原则提供了指导框架，但其在实际落地中困难重重，尤其是在制药企业等大型组织内。本文阐述了诺和诺德研究与早期开发部门如何利用基于本体的数据管理（OBDM）战略实现数字化转型。我们既包含技术蓝图，也涵盖组织变革管理方法。进一步探讨了此类OBDM生态系统如何在以人工智能驱动的数据联邦与发现这一组织数字化愿景中发挥关键作用。本文旨在分享经验教训，以促进与面临类似挑战的各方展开对话，共同推动数据管理、语义学及数据驱动药物发现领域的发展。